Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.03 | N/A | -13.60% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.03 | N/A | -13.60% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to long-term goals without offering specific future guidance.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on its strategic initiatives despite the EPS miss.
PTC Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. Investors may be concerned about the lack of revenue data and forward guidance. The stock's reaction indicates cautious sentiment as the company navigates its strategic initiatives without clear financial expectations for the future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TELADOC HEALTH INC
Feb 22, 2022